An exploratory study of susceptible factors to tolvaptan treatment in hepatic edema

An exploratory study of susceptible factors to tolvaptan treatment in hepatic edema - An exploratory study of susceptible factors to tolvaptan treatment in hepatic edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017318

Enrollment

Registered

2015-04-28

Start date

2015-04-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis with refractory hepatic edema

Interventions

Tolvaptan 3.75mg or 7.5mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Liver cirrhosis with refractory hepatic edema despite undergoing therapy with furosemide 20mg/day or more and spironolactone 25mg/day or more 2)Patients obtained written informed consent

Exclusion criteria

Exclusion criteria: 1)Alcoholic hepatitis and cirrhosis patients in continued drinking 2)Patients with overt hepatic encephalopathy 3)Patients with requiring treatment for esophageal, gastric or rectal varices 4)Hepatocellular carcinoma with life expectancy less than 3 months 5)The anuria patints (including dialysis patients) 6)Patients with urinary excretion failure 7)Patients with oral intake difficulty 8)Patients receiving albumin within 7 days before the test 9)Patients with unsuitable condition for this study

Design outcomes

Primary

Measure	Time frame
Decrease of body weight after 7 days of tolvaptan treatment	—

Secondary

Measure	Time frame
SNP analysis Blood biochemical findings Body composition change by In body Symptom change by ASI-7	—

Countries

Japan

Contacts

Public ContactYoshitaka Arase

Tokai University School of Medicine Department of Gastroenterology and Hepatology

arase@tokai-u.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026